LENZ Therapeutics (NasdaqGS:LENZ) FY Conference Transcript

LENZ Therapeutics FY Conference Summary Company Overview - Company: LENZ Therapeutics (NasdaqGS:LENZ) - Product: VIZZ, a presbyopia eye drop launched in October 2025 Key Points Product Launch and Market Reception - VIZZ is a once-a-day eye drop that can replace reading glasses, providing up to 10 hours of near vision improvement [2][11] - The product has received positive feedback from both doctors and patients, with anecdotal reports of efficacy lasting up to 12 hours [11] - The company has distributed samples to approximately 15,000 target doctors, encouraging patient trials [4] Clinical and Real-World Efficacy - Clinical studies showed strong results, and real-world experiences confirm that the product works effectively [3] - Patients are reportedly moving from single packs to multi-packs, indicating satisfaction and stickiness with the product [5] Doctor Engagement and Sales Strategy - The number of prescribing doctors has grown from 6,500 in January to a rapidly increasing number, with a focus on making VIZZ a regular part of patient discussions [6] - The sales force is being expanded to meet demand from doctors outside the initial target group [7][34] Direct-to-Consumer (DTC) Campaign - A DTC campaign launched in January 2026 features spokesperson Sarah Jessica Parker, aiming to increase patient awareness and demand [27][30] - Early indicators show a significant increase in website visits and patient inquiries, although it may take time to translate into prescriptions [28][57] Market Potential - The presbyopia market is estimated to have 128 million potential patients, with a projected $3 billion market size at a 6% penetration rate [42] - The company is focused on converting trial users into regular customers, with encouraging refill rates observed [43][44] Side Effects and Safety - Mild and transient side effects, such as hyperemia (eye redness), have been reported but are generally short-lived [14][15] - Concerns regarding retinal detachments have been addressed, with the company reporting only one case linked to a patient with a history of retinal issues [18][19] Competitive Landscape - The company believes that the market can support multiple effective products, emphasizing the unique efficacy of VIZZ compared to competitors [61][62] - The management is confident in the product's performance and its ability to capture market share [63] Investor Insights - The company is focused on execution and driving script growth, with a healthy cash balance allowing for continued investment in sales and marketing [65] - Management believes that the share price will reflect the company's performance as it successfully connects product efficacy with market demand [65] Demographics and Usage Trends - The user demographic skews 60% female and 40% male, primarily aged 45-65, but the product is effective across a broader range [48] - The pricing strategy includes a retail price of $79 per pack, with a net price of approximately $60 after discounts [49] Conclusion - LENZ Therapeutics is in the early stages of launching VIZZ, with positive initial feedback and a strong market potential. The company is actively expanding its sales force and DTC efforts to drive adoption and ensure long-term success in the presbyopia market [66]